Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment

Cutis

Volumn 74, Issue 2, 2004, Pages 123-130

  Thorneycroft, Ian H ^a,d   Gollnick, Harald ^b   Schellschmidt, Ilka ^c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Berlex Labs and Wyeth Pharmaceut

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; MINERALOCORTICOID ANTAGONIST; SEX HORMONE BINDING GLOBULIN;

ABDOMINAL PAIN; ACNE; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EVALUATION; FEMALE; FIBROCYSTIC BREAST DISEASE; HEADACHE; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MIGRAINE; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SEBUM SECRETION; SKIN DEFECT; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; NORGESTREL; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 4444371712     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol. 2002;3:571-578.
2. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57-67.
3. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs. 2003;63:1579-1596.
4. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dematol. 1997;37:746-754.
5. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615-622.
6. van Vloten WA, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(suppl 4):2-15.
7. Gollnick H, Albring M, Brill K. The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type. Ann Endocrinol (Paris). 1999;60:157-166.
8. Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51:188-215.
9. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone. a review of its use as an oral contraceptive. Treat Endocrinol. 2003;2:49-70.
10. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761:311-335.
11. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25-34.
12. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1-S37.
13. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124-134.
14. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105-111.
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Choice of Control Group and Related Issues in Clinical Trials E10. July 20, 2000.
16. The European Agency for the Evaluation of Medicinal Products. Committee for proprietary medicinal products (CPMP). Points to Consider on Switching Between Superiority and Noninferiority. London, England: July 27, 2000.
17. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999;60:255-262.
18. Lemay A, Dewailly SD, Grenier R, et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 1990;71:8-14.
19. Wishart JM. An open study of Triphasil and Diane 50 in the treatment of acne. Australas J Dermatol. 1991;32:51-54.
20. Palatsi R, Reinila M, Kivinen S. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne. Acta Derm Venereol. 1986;66:225-230.
21. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29-38.
22. Darney PD. The androgenicity of progestins. Am J Med. 1995;98:104S-110S.